drugset / Trial / NCT00351832
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd compared to placebo in patients with type 2 diabetes.
Timeline
- Start
- 2006-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vildagliptin | Other / unclassified | 50 mg | Oral |
| Subject | Vildagliptin | Other / unclassified | 100 mg | Oral |